multiple sclerosis
Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
July 28, 2025Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
Sanofi announce positive phase 2 data for MS drug frexalimab
June 1, 2023Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis
French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …
Biogen announces collaboration on novel MS treatment
July 13, 2021Manufacturing and Production multiple sclerosis
Biogen and InnoCare Pharma have announced a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase …
Novartis multiple sclerosis treatment recommended by NICE
April 20, 2021Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news
NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …
Janssen’s multiple sclerosis treatment recommended by EMA
March 29, 2021Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis
Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …
NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic
March 3, 2021Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis
NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …
CHMP recommends marketing authorisation for Novartis’ Kesimpta
February 1, 2021Sales and Marketing Novartis, multiple sclerosis
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorisation of Novartis’ Kesimpta (ofatumumab) for …
Biogen’s IM Plegridy gets EU approval
January 6, 2021Research and Development Biogen, multiple sclerosis
The European Commission has approved Biogen’s Plegridy (peginterferon beta-1a), a new intramuscular (IM) injection for the treatment of relapsing-remitting multiple …
Biogen agrees to pay $22m to settle kickback allegations
December 18, 2020Medical Communications Biogen, multiple sclerosis
Biogen has agreed to pay $22 million to put an end to an investigation into claims that it illegally used …
FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis
October 7, 2020Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis
Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …
BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis
May 28, 2020Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis
Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …
FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry
March 26, 2020Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma
Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …
Biogen stock surges following patent victory over Mylan for Tecfidera
February 6, 2020Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera
Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …
Multiple sclerosis market to be worth $32.9bn in 2028
December 11, 2019Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma
The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …
